The Copilot Delusion: Why “We Only Use Copilot” Is Not an AI Governance Strategy

28 Jul, 2026

In pharma, AI governance sits at the intersection of enterprise technology risk, regulated-process controls, and emerging AI law. The question is no longer just whether a tool is enterprise-approved. It is whether the specific use of that tool is understood, classified, governed, documented, and, where needed, validated for the context in which it is being used.

Read full website blog...

Write a comment ...

Eularis

Eularis helps you quickly solve the biggest challenges within Healthcare with Artificial Intelligence and Futuretech-Led solutions.

1 Follower
3 Following

Why Most Pharma AI Strategies Fail the CFO Test
Most pharmaceutical organizations do not struggle to explain what their AI programmes do. They struggle to explain, in financial terms, why those programmes deserve sustained investment.
Eularis
Al created a trust crisis and nobody is talking about it
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dan Pratl, founder and CEO of Quadron Inc, about a trust problem emerging as AI moves deeper into pharma: how do organisations preserve confidence when more work is generated, shaped and accelerated by machines?
Eularis
How AI Features Make Social Listening More Accurate
There are millions of patients and professionals discussing different therapies, drugs, and diseases on various social media, forums, and other websites. In case of pharma companies, such discussions are a treasure trove of patient experience information that is not gained in clinical settings.The issue here is that the social listening technology that was used before wasn’t designed to deliver insights this complex and deep.
Eularis
The Diagnostic Room: You didn't have an Al problem. You had a capability problem....
In this solo episode of Al For Pharma Growth, Dr Andree Bates explores why many pharma teams do not have an Al problem at all. They have a capability problem.
Eularis
AI in Drug Discovery From Data to New Medicines
This infographic represents how AI in Drug Discovery transforms complex data into new medicines by identifying drug targets, discovering promising compounds, predicting safety, optimizing candidates, accelerating preclinical research, and supporting faster development decisions.
Eularis
What the EU AI Act Postponement Actually Means for Pharma AI Governance Globally
For many pharma and biotech leaders, that sounded like relief. In one sense, it is. The industry has been preparing against a difficult implementation path, with legal uncertainty, unfinished standards, unresolved questions about overlap with sectoral rules and uneven readiness across both companies and regulators. More time matters.
Eularis
Importance of Digitalization in Pharmaceutical Industry for Smarter Growth
The pharmaceutical sector is currently witnessing a revolution as the evolution in technology transforms the way businesses perform research, development, production, marketing, and delivery of healthcare solutions. In such an environment, comprehending the significance of digitalization in the pharmaceutical industry becomes crucial for those businesses looking to enhance efficiency, cater to changing customer demands, and sustain their growth.
Eularis
What Is Big Tech’s Role in Healthcare and How Is It Transforming Medicine?
Healthcare is evolving quickly as technology transforms how patients receive medical care, physicians make decisions, and pharma companies develop solutions. Large tech companies, including Google, Amazon, Microsoft, Apple, and IBM, have started entering the healthcare industry.
Eularis
From Bench to Boardroom: How One Geneticist is Quietly Reshaping the Future of Healthcare...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Bret Bostwick from Breyer Capital about the rare path from genetics, clinical medicine and drug development into venture capital, and what that perspective reveals about the future of healthcare innovation.
Eularis
How AI Is Changing Pharma and Biotech Across the Healthcare Industry
Healthcare is currently experiencing one of its biggest transformations in history, with artificial intelligence in pharma and biotech being the driving force behind this revolution. The impact of this technology spans across the entire healthcare industry from drug discovery to improved patient treatment and care.
Eularis
Generative AI for Pharma: Transforming Drug Discovery and Development
For many decades the pharmaceutical industry has always struggled with one major issue: the development of drugs takes years of hard work and lots of money to develop a drug, and the majority of attempts fail even before becoming available to patients. However, all these facts have become a norm, “the cost of doing business,” in the industry for many decades.
Eularis
Generative AI for Pharma Driving Smarter Drug Innovation
This infographic showcases how Generative AI is driving smarter drug innovation across the pharmaceutical industry. It highlights Eularis' expertise in accelerating drug discovery, improving clinical development, strengthening AI governance, and enabling future-ready growth through strategic, trusted, and sustainable AI solutions.
Eularis
From Population Models to Personal Intelligence: Rethinking Biological Data
For most of modern medicine, biological data has been built around population averages: what people like you might experience, rather than what you personally will. In this episode, Dr Andree Bates speaks with Ken Clark, co-founder and CEO of Enigma Genetics, about moving from population models to personal intelligence, and what it could mean for patients, pharma and the future of biological data.
Eularis
From Use Case to Working AI Agent Inside Your Pharma Environment
Functional leaders in regulatory affairs, medical affairs, commercial, and market access have now seen enough AI demonstrations to understand what is possible. They have watched an agent draft a literature summary in a few minutes. They have seen AI support medical information triage, assemble competitive landscapes and pre-populate sections of regulatory submissions.
Eularis
Exploring the Benefits of Nanobots in Medicine for Better Outcomes
The goal of all medical practitioners has always been precision. However, up till recently, precision in medicine was achieved through larger scans, more accurate imaging, and medicines that were customized for specific issues. The future of precision medicine lies in technology that is very tiny.
Eularis
The Growing Impact of Nanobots in Medicine and Patient Care
Have you ever thought about tiny robots moving inside your body to identify and combat an illness at its source? Although it sounds like something from a science fiction film, nanobots in medicine are actually making a swift transition from study paper pages to actual healthcare. They are also bringing about an incredible change.
Eularis
The Intelligence Gap: Why Pharma's Biggest Deals Are Being Lost Before They Even Know They're Competing...
In pharma, the biggest deals are increasingly won or lost before a formal process even begins. In this episode, Dr Andree Bates interviews Andrey Doronichev, co-founder and CEO of Bioptic, about the “intelligence gap” in business development, licensing, and corporate strategy, and why many companies are losing opportunities before they even know they’re competing.
Eularis
AI in Life Sciences Accelerating Research and Development
The following infographic shows how AI in Life Sciences is helping accelerate research and development through smarter data analytics, faster drug discovery, better clinical development, informed decision-making, and forward-thinking innovations. Eularis assists life sciences companies use AI to gain growth and transformation.
Eularis
The Role of AI in Solving Clinical Trial Enrollment Challenges
Enrolment isn’t a “soft” operational risk in drug development – it’s the hard constraint that quietly determines whether a promising asset reaches patients on time or bleeds value in limbo. In today’s clinical landscape, recruitment timelines are missed so routinely that it has become the norm rather than the exception, with widely cited analyses indicating that roughly 80% of trials experience delays driven by enrolment.
Eularis

Eularis

Eularis helps you quickly solve the biggest challenges within Healthcare with Artificial Intelligence and Futuretech-Led solutions.

1 Follower

3 Following

Why Most Pharma AI Strategies Fail the CFO Test

Eularis

Al created a trust crisis and nobody is talking about it

Eularis

How AI Features Make Social Listening More Accurate

Eularis

The Diagnostic Room: You didn't have an Al problem. You had a capability problem....

Eularis

AI in Drug Discovery From Data to New Medicines

Eularis

What the EU AI Act Postponement Actually Means for Pharma AI Governance Globally

Eularis

Importance of Digitalization in Pharmaceutical Industry for Smarter Growth

Eularis

What Is Big Tech’s Role in Healthcare and How Is It Transforming Medicine?

Eularis

From Bench to Boardroom: How One Geneticist is Quietly Reshaping the Future of Healthcare...

Eularis

How AI Is Changing Pharma and Biotech Across the Healthcare Industry

Eularis

Generative AI for Pharma: Transforming Drug Discovery and Development

Eularis

Generative AI for Pharma Driving Smarter Drug Innovation

Eularis

From Population Models to Personal Intelligence: Rethinking Biological Data

Eularis

From Use Case to Working AI Agent Inside Your Pharma Environment

Eularis

Exploring the Benefits of Nanobots in Medicine for Better Outcomes

Eularis

The Growing Impact of Nanobots in Medicine and Patient Care

Eularis

The Intelligence Gap: Why Pharma's Biggest Deals Are Being Lost Before They Even Know They're Competing...

Eularis

AI in Life Sciences Accelerating Research and Development

Eularis

The Role of AI in Solving Clinical Trial Enrollment Challenges

Eularis